Lisa A. Thompson, PharmD, BCOP

Lisa A. Thompson, PharmD, BCOP

Lisa A. Thompson, PharmD, BCOP, Clinical Pharmacy Specialist in Oncology, Kaiser Permanente, Colorado

Most Recent Articles by Lisa A. Thompson, PharmD, BCOP

MDS, AML a Risk With PARP Inhibitors in <i>BRCA</i> Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

By

What is the concern behind PARP inhibitors and leukemia?

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

By

Why was the ESA APPRISE risk evaluation and mitigation strategy program discontinued?

Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting

Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting

By

Intractable hiccups can be especially problematic in the advanced cancer and palliative care settings. Dr Thompson, an oncology pharmacist, reviews options for effective medical management of this condition.

Difference Between CDK Inhibitors

Difference Between CDK Inhibitors

By

What is the difference between the CDK inhibitors?

Affect of Daratumumab on Laboratory Blood Test Results

Affect of Daratumumab on Laboratory Blood Test Results

By

Do monoclonal antibodies other than daratumumab cause false positives in the blood antibody screen and crossmatch obtained prior to a transfusion?

More Articles by Lisa A. Thompson, PharmD, BCOP

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs